Fig. 7: Resistance to lapatinib increases the sensitivity of OAC tumours to NRF2 inhibition by brusatol.
From: NRF2-mediated persistent adaptation of oesophageal adenocarcinoma cells to HER2 inhibition
OE19-PT (A), OE19-RT1 (B), and OE19-PT cells stably transduced with Ctrl (empty vector) or NRF2 encoding viral particles (C) were subcutaneously implanted into the flank of SCID mice. Animals carrying small tumours (approximately 80–120 mm3) subsequently received lapatinib (100 mg/Kg) or brusatol (2 mg/Kg) by oral gavage. Tumour size was measured daily for the duration of the experiment. The data are presented as the volume of tumour size (n = 4 or 5 mice in each group). Representative pictures of tumour grafts excised from mice sacrificed at the end of the experiment are shown. One-way ANOVA (A, B) and Wilcoxon rank sum test (C) were utilised to analyse statistical differences between groups.
